Greenacre J K, Coxon A, Petrie A, Reid J L
Lancet. 1976 Aug 21;2(7982):381-4. doi: 10.1016/s0140-6736(76)92403-x.
The therapeutic efficacy and side-effects of two preparations of levodopa with extracerebral decarboxylase inhibitors have been compared in 19 patients with idiopathic parkinsonism in a blind randomised crossover trial. The mean daily dose of levodopa was 658 +/- 64 mg/day (mean +/- S.E.M.) when given together with carbidopa 66 mg/day and 605 +/- 59 mg/day when levodopa was combined with benserazide 151 mg/day. There was no significant difference between the treatment regimens either in beneficial effects on parkinsonian symptoms and signs or in the adverse effects of levodopa assessed by a clinical observer unaware of the treatment given. Of the 19 patients studied, 9 preferred the carbidopa preparation, 8 preferred the benserazide preparation, and 2 had no preference. It is concluded that there is no significant difference in therapeutic effects or adverse reactions between the two commercially available decarboxylase inhibitor-containing preparations. Central-nervous-system actions and side-effects depend on the daily dose of levodopa, regardless of the different ratios of decarboxylase inhibitors to levodopa.
在一项双盲随机交叉试验中，对19例特发性帕金森病患者比较了两种含脑外脱羧酶抑制剂的左旋多巴制剂的治疗效果和副作用。当左旋多巴与卡比多巴66毫克/天联用时，左旋多巴的平均日剂量为658±64毫克/天（平均值±标准误）；当左旋多巴与苄丝肼151毫克/天联用时，平均日剂量为605±59毫克/天。在对帕金森症状和体征的有益作用方面，以及在由不知道所给予治疗的临床观察者评估的左旋多巴的不良反应方面，两种治疗方案之间均无显著差异。在所研究的19例患者中，9例更喜欢卡比多巴制剂，8例更喜欢苄丝肼制剂，2例无偏好。结论是，两种市售的含脱羧酶抑制剂制剂在治疗效果或不良反应方面无显著差异。中枢神经系统作用和副作用取决于左旋多巴的日剂量，而与脱羧酶抑制剂与左旋多巴的不同比例无关。
